Gilead Sciences (NASDAQ: GILD)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Gilead Sciences Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Gilead Sciences Company Info
Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide.
News & Analysis
A list of high-yielding dividend stocks to consider buying now.
Here are the five best biotech ETFs to invest in right now.
The S&P 500 has outperformed Gilead over the past five years.
The healthcare sector is a good place to find recession-proof stocks.
Should you buy Gilead Sciences stock despite its poor track record?
Both companies are steals at current levels.
The company's dominant HIV therapies and growing oncology pipeline are delivering.
Would you have been better off investing in the S&P 500?
Valuation
Podcast Episodes
Here’s how CAR-T therapies did in their first full year on the market.
Declining sales increase the stakes for Gilead's most-promising R&D projects.
The FDA approved the world's first CAR-T therapy on Wednesday, one month ahead of schedule, and only days after Gilead Sciences announced it’s buying CAR-T powerhouse Kite Pharma in a deal valued at $11.9 billion.
Celgene's and Gilead Sciences’ Q2 2017 results are fueling gains in their stock prices, but is one of these stocks doing better than the other?
Earnings Transcripts
GILD earnings call for the period ending March 31, 2023.
GILD earnings call for the period ending December 31, 2022.
GILD earnings call for the period ending September 30, 2022.
GILD earnings call for the period ending June 30, 2022.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.